BioRestorative Therapies (BRTX) Payables (2010 - 2025)

BioRestorative Therapies (BRTX) has reported Payables for 16 consecutive years, with $2.7 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Payables fell 8.76% year-over-year to $2.7 million; the trailing twelve-month figure through Dec 2025 stood at $2.7 million (down 8.76% YoY), and the FY2025 full-year result was $2.7 million, down 8.76% from the prior year.
• Payables eased to $2.7 million in Q4 2025 per BRTX's latest filing, from $2.8 million in the prior quarter.
• Across five years, Payables topped out at $14.4 million in Q1 2022 and bottomed at $50827.0 in Q4 2021.
• Historically, Payables has averaged $4.2 million across 5 years, with a median of $3.1 million in 2024.
• The sharpest annual moves came in 2021 and 2022: Payables sank 97.56% in 2021, then surged 11139.37% in 2022.
• Over 5 years, Payables stood at $50827.0 in 2021, then soared by 11139.37% to $5.7 million in 2022, then tumbled by 69.66% to $1.7 million in 2023, then jumped by 73.3% to $3.0 million in 2024, then dropped by 8.76% to $2.7 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $2.7 million, $2.8 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.